Healthcare Providers and Services
Company Overview of Miraca Life Sciences, Inc.
Miraca Life Sciences, Inc. engages in the development and commercialization of anatomic pathology services in the fields of dermatology, hematology, gastroenterology, and urology in the United States. It focuses on the development of a blood-based diagnostics platform to address unmet clinical needs in the gastrointestinal cancer spectrum, including screening and diagnosis, and prognosis and therapeutic guidance. The company also provides microscopy and immunohistochemistry with integrated molecular diagnostic services; and UroVysion, a deoxyribonucleic acid-based urine test that detects key genetic changes in bladder cells. In addition, it offers general surgery pathology services. Further,...
6655 North MacArthur Boulevard
Irving, TX 75039
Founded in 1996
Key Executives for Miraca Life Sciences, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2013.
Miraca Life Sciences, Inc. Key Developments
Modernizing Medicine, Inc. and Miraca Life Sciences, Inc. Partner to Create Enhanced EMR and Pathology Lab Integration
Sep 25 13
Modernizing Medicine, Inc. and Miraca Life Sciences, Inc. announced that they are partnering to develop an enhanced diagnostic data bridge. Pathologists normally analyze tissue samples with limited clinical background on patients, which can delay accurate diagnoses. EMA dermatologists and MLS pathologists will be able to share additional diagnostic information, which can help the pathologist create a more timely, informed and accurate analysis. Modernizing Medicine's user-friendly EMA adapts to each healthcare provider's unique style of practice and integrates seamlessly into the practice's workflow, saving physicians and their staff time and increasing efficiencies. EMA's cloud-based approach to collecting and storing patient information enables physicians to utilize the EMA Network(TM) to create, visualize and consume treatment data to better care for their patients.
Caris Life Sciences, Inc. Launches Caris Target Now(TM) Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary
Jun 26 12
Caris Life Sciences, Inc. announced the launch of Caris Target Now(TM) Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the original Caris Target Now comprehensive molecular profiling service offering for all solid tumors. Caris Target Now Select incorporates updated, evidence-based technology platforms to determine the genomic information unique to a patient's tumor based on the presence of relevant biomarkers. In addition to providing focused biomarker profiles designed for earlier-stage cancer patients, it offers the advantages of known "on-Compendium-only" drug associations, faster turnaround time, the capability to derive meaningful results from smaller tissue samples, up to 30 reported biomarkers per patient (depending on tumor type), and -- for the first time -- Clinical Trials Connector(TM), a service that enables biomarker-specific clinical trial matching.
Caris Life Sciences, Inc. Announces the Utility of its Caris Target Now(TM) Evidence-Based Molecular Profiling Service in the Characterization of Breast and Head and Neck Cancers
Jun 2 12
Caris Life Sciences, Inc. announced the utility of the company's Caris Target Now(TM) evidence-based molecular profiling service in the characterization of breast and head and neck cancers. In a poster presentation, Gargi Basu and colleagues at Caris Life Sciences, presented results from the first study providing a comprehensive review of transducin-like enhancer of split 3 (TLE3) expression in breast cancer subtypes. They described TLE3 as a transcriptional repressor that influences tumor growth and microtubule stability; its expression in epithelial tumor cells may reflect that these cells require the expression of TL3 to maintain their undifferentiated state. The expression of TLE3 is also associated with response to taxane therapy in patients with breast cancer. Working with tumor cells collected from 978 breast cancer patients, the investigators employed two different technological platforms used in Caris Target Now -immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) - to gather information on four biomarkers: TLE3 (M-201), ER(1D5), PR(PgR636), and human epidermal growth factor receptor 2 (HER2)/neu (Polyclonal). IHC analysis of the four biomarkers was conducted at the protein level, and FISH was used to determine amplification of HER2/neu. Samples were then sub-classified as hormone receptor (HR)-positive (i.e., estrogen receptor [ER]-positive and/or progesterone receptor [PR]- positive), HER2-positive (either at the protein level or amplified by FISH), or triple-negative (i.e., lacking in ER, PR, and HER2/neu). Overall, 351 (36%) of the patients were HR-positive, 150 (15%) were HER2-positive, and 477 (49%) were triple-negative. TLE3 was expressed in 82% of the HR-positive patients, 73% of the HER2-positive patients, and 61% of the triple-negative patients. To further investigate TLE3 expression in the patient subtypes, Dr. Basu and colleagues performed a pairwise Fisher's Exact Test between the various pairs; this analysis revealed that for all pairs, the ratios of TLE3-expressing individuals were significantly different. The difference was observed between the HR-positives and the triple-negatives (82% vs. 61%, respectively; p=2.509e-10), suggesting that the HR-positives have a higher likelihood of responding to taxane therapy. The HER2-positives, at 73%, had a ratio that was significantly higher than the triple-negatives and significantly lower than the HR-positives. In a separate presentation, a team of Caris Life Sciences researchers led by Rebecca Feldman presented results from the first analysis of biomarker expression profiles in head and neck squamous cell carcinoma (HNSCC) based on p53 status. They noted that HPV positive patients tend to carry the wildtype p53 tumor suppressor and have an overall better prognosis compared to non-carriers of the virus who are more likely to be p53 mutated. Insight to this difference in prognosis was pursued by comparing the biomarker expression profiles of p53 wildtype and mutated patients. The researchers performed TP53 gene sequencing on the DNA of 52 patients with HNSCC whose samples previously underwent IHC and FISH testing with Caris Target Now. Thirteen (25%) of the patients were found to have mutated copies of p53. Of the various biomarkers assayed and analyzed, only EGFR and HER2 (p=0.002 and p=0.004, respectively) were significantly differentially expressed in wildtype compared to mutated p53. Matched-pair analysis in the subgroup of patients with mutated p53 showed no significant trend in terms of EGFR status (p=0.763), however half of the mutated patients with EGFR FISH data were EGFR FISH positive. In the 39 patients with wildtype p53, there was a strong association with EGFR non-amplification (n=28, 72%; p<0.001) and HER2 negativity (n=38, 97%; p<0.001).
Similar Private Companies By Industry
Recent Private Companies Transactions